Betta Pharmaceuticals Co., Ltd.
84
8
11
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
2.4%
2 terminated/withdrawn out of 84 trials
90.5%
+4.0% vs industry average
21%
18 trials in Phase 3/4
5%
1 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (84)
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Role: lead
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Role: lead
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Role: lead
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Role: lead
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
Role: lead
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Role: collaborator
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
Role: lead
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Role: lead
A Study of BPI-460372 in Advanced Solid Tumor Patients
Role: lead
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
Role: lead
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
Role: collaborator
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
Role: lead
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Role: lead
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Role: lead
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
Role: lead
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Role: collaborator
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Role: lead
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Role: lead
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
Role: lead
X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Role: lead